Thus, targeting antiapoptotic BCL-2 family proteins may be an emerging therapeutic strategy for patients with cisplatin-resistant ovarian cancer since it allows the induction of DRP1-dependent apoptotic mitochondrial fission [66,88]. Here, BCL2 is linked to ovarian carcinoma.